The Patterson Analysis

Inside the new Louisville hub where automation and an 'end-of-runway' strategy with UPS aim to redefine speed and precision in drug delivery.

A landmark partnership aims to channel a century of oil and gas know-how into the geothermal sector, promising to unlock a vast, clean energy source.

Lyons & Simmons' recent award is more than a trophy. It signals a strategic shift where plaintiff's firms drive industry-wide safety reforms.

A new joint venture aims to zap age-old lumber processing problems with radio waves, promising faster, better, and more efficient wood production.

The nationwide launch of Ritual's prenatal vitamin at Costco is more than a distribution win; it's a stress test for a new retail model based on clinical proof.

Zac Brown Band's cruise giveaway is more than a thank you; it's a blueprint for deep brand integration and a new, high-stakes era of fan engagement.

A landmark study by the Payne Center and Gallup proves HBCUs outperform national benchmarks in graduate success. The data is clear, but what does it mean for execution?

After two decades and over $9 million, Purina's landmark partnership with the AKC Canine Health Foundation has ended. We analyze its legacy and what comes next.

Solitics' new agentic AI, Saai, aims to automate bank marketing. But beyond the hype, can it navigate the industry's brutal integration and compliance hurdles?

Solmate Infrastructure is not just partnering with Anagram; it's executing a blueprint for dominance by assembling a coalition of experts to capture Solana's institutional wave.

Corsair's minority stake in Bitfocus isn't just an investment; it's a calculated pivot into the pro broadcast world, leveraging a decade of grassroots synergy.

Green Thumb Industries' new Hanover dispensary is more than retail growth. It's a calculated move in a key market, blending strategic expansion with a savvy model.

Patterson Analysis: While foundation businesses deliver record profits, Umicore's battery segment relies on contractual clauses, not volume growth.

As specialty insurer Trisura Group readies its Q2 results, investors are watching to see if its growth can navigate market shifts and justify high expectations.

Karyopharm plans an accelerated FDA filing for its selinexor combo in myelofibrosis. The move hinges on a key surrogate endpoint and a race against competitors.

A year of delays and a stagnant €14.10 offer have ignited shareholder dissent, with Petrus Advisers leading the charge to reject Tata's bid for Iveco.

A new certification using AI and satellite data has covered 90% of US-bound Mexican avocados in just two years. Is this the blueprint for sustainable supply chains?

As Vuzix prepares its Q2 2026 earnings call, investors will look past the numbers to a bigger question: can its pivot to an OEM model unlock its AR potential?

Karyopharm's stock plummets after a key cancer trial fails, forcing a strategic retreat and a hard pivot toward more promising assets in its pipeline.

A $72k donation for St. Jude is just the start. We analyze the operational model that turns member miles into life-saving funds and strategic brand value.